Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR
Open Access
- 9 September 2021
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 157, 153-164
- https://doi.org/10.1016/j.ejca.2021.07.029
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Sorafenib for patients with differentiated thyroid cancer – Authors' replyThe Lancet, 2015
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialThe Lancet, 2014
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialThe Lancet Oncology, 2013
- Selective Use of Radioactive Iodine in Intermediate-Risk Papillary Thyroid CancerJAMA Otolaryngology–Head & Neck Surgery, 2012
- Cancers réfractaires de la thyroïdeLa Presse Médicale, 2011
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyThe Lancet Oncology, 2010
- Harvesting the Low-Hanging Fruit: Kinase Inhibitors for Therapy of Advanced Medullary and Nonmedullary Thyroid CancerJournal of Clinical Endocrinology & Metabolism, 2010
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyJournal of Clinical Endocrinology & Metabolism, 2006